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Friedreich ataxia is a multi-system autosomal recessive inherited disorder primarily
caused by homozygous GAA repeat expansion mutations within intron 1 of the frataxin
gene. The resulting deficiency of frataxin protein leads to progressive mitochondrial
dysfunction, oxidative stress, and cell death, with the main affected sites being the large
sensory neurons of the dorsal root ganglia and the dentate nucleus of the cerebellum.
The GAA repeat expansions may be pure (GAA)n in sequence or may be interrupted
with regions of non-GAA sequence. To our knowledge, there has been no large-scale
study of FRDA patient DNA samples to determine the frequency of large interruptions
in GAA repeat expansions. Therefore, we have investigated a panel of 245 Friedreich
ataxia patient and carrier DNA samples using GAA repeat PCR amplification and MboII
restriction enzyme digestion. We demonstrate that the vast majority (97.8%) of Friedreich
ataxia GAA repeat expansion samples do not contain significant sequence changes that
would result in abnormal MboII digestion profiles, indicating that they are primarily pure
GAA repeats. These results show for the first time that large interruptions in the GAA
repeats are very rare.
Keywords: Friedreich ataxia, FRDA, frataxin, GAA repeat mutation, GAA repeat interruptions, trinucleotide repeat
expansion disease
INTRODUCTION
Friedreich ataxia (FRDA) is a multi-system autosomal recessive inherited disorder characterized by
neurological features of ataxia, dysarthria, weakness, ocular fixation instability, deep sensory loss,
and visual and hearing impairment, together with non-neurological features such as hypertrophic
cardiomyopathy, diabetes mellitus, kyphoscoliosis, and foot deformities (Reetz et al., 2015). The
mean age of onset of FRDA is 15 years, with most cases developing by age 25, although rare
cases of late onset FRDA (26–39 years), or very late onset FRDA (40 years or over) have been
reported (Durr et al., 1996; Filla et al., 1996). FRDA is primarily caused by homozygous GAA
trinucleotide repeat expansion mutations within intron 1 of the frataxin (FXN) gene, leading to
deficit of the essential mitochondrial protein frataxin. The resulting deficiency of frataxin protein
leads to progressive mitochondrial dysfunction, oxidative stress, and cell death, with the main
affected sites being the large sensory neurons of the dorsal root ganglia and the dentate nucleus
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of the cerebellum (Campuzano et al., 1996, 1997). The number
of GAA repeats in unaffected individuals generally ranges from
6 to 27 repeats, although rare cases of 33 to 130 repeats have
been identified (Cossee et al., 1997; Montermini et al., 1997;
Ohshima et al., 1999). In contrast, approximately 96% of FRDA
patients have homozygous GAA repeat expansions ranging from
44 to 1,700 repeats, with 600–900 GAA repeats being the
most common. The remaining FRDA patients are compound
heterozygous for a GAA repeat expansion and a second FXN
mutation. The age of onset is inversely correlated with the GAA
repeat number, particularly for the shorter allele (GAA1), with a
prediction of 2.3 years earlier onset for every 100 GAA repeats
added to GAA1 (Reetz et al., 2015). Thus, the GAA1 allele is
considered to give the closest genotype–phenotype relationship.
However, the GAA repeat size accounts for only approximately
36% to 56% of the variation in age of onset (Durr et al., 1996;
Filla et al., 1996; Reetz et al., 2015). This suggests that there
are other contributory mechanisms such as somatic mosaicism,
interruptions in the GAA repeat sequence, and other modifying
genes or environmental factors, which influence age of onset
(Filla et al., 1996; Pandolfo, 2009; Reetz et al., 2015). Earlier age
of onset increases the frequency and severity of neurological and
non-neurological symptoms. In contrast, patients with late-onset
disease have a milder phenotype and slower disease progression
(Durr et al., 1996).
In the majority of cases of FRDA, the GAA repeat expansion
mutations have been characterized only in terms of the overall
repeat size rather than sequence content, which can be either pure
GAA or interrupted GAA. Where full sequencing of FXN GAA
repeats has been possible due to comparatively short repeats (up
to approximately 130 repeats), there are reports of interrupted
GAA repeat expansion sequences, such as (GAGGAA)5−9 or
(GAAGGA)65, and these are associated with either absence of
FRDA disease phenotype (Cossee et al., 1997; Montermini et al.,
1997; Ohshima et al., 1999) or atypical mild late-onset or very
late-onset FRDA disease phenotype (Cossee et al., 1997; Epplen
et al., 1997; Moseley et al., 1998; McDaniel et al., 2001; Sharma
et al., 2004; Stolle et al., 2008). In vitro studies have shown
that interrupted GAA repeats inhibit triplex formation, alleviate
transcription inhibition, and reduce repeat instability (Ohshima
et al., 1999; Sakamoto et al., 2001). Therefore, it is thought
that interruptions in the GAA repeat sequence can result in
maintenance of FXN expression levels and reduced somatic
instability of GAA repeats when compared to similar sized pure
GAA repeats, thereby impacting upon FRDA disease progression.
Further studies have shown that pure GAA repeats are stable up
to a threshold of 44 repeats, after which they become unstable
(Sharma et al., 2004). In a study of FRDA carriers, 107 pure GAA
repeats were unstable, whereas 114 interrupted GAA repeats
were stable by small-pool PCR of blood samples (Pollard et al.,
2004). Also a (GAA)90(GAAAGAA)9(GAA)20 interrupted 112
GAA repeat has been shown to stably transmit through two
generations (Cossee et al., 1997). Finally, somatic instability of
the GAA1 allele has been identified in two FRDA patients who
have one large GAA2 allele and a small GAA1 allele of either 44
or 66 repeats, while their sibling with one large GAA2 allele and
one somatically stable GAA1 allele of 37 repeats was clinically
normal (Sharma et al., 2004). So, it would appear that somatic
instability may have a significant role to play in FRDA disease
progression and interrupted GAA repeats are likely to confer
some protection in the form of somatic stability and maintenance
of FXN expression levels.
Analysis of the much more frequent large GAA2 alleles
(>130 repeats) for the presence or absence of interruptions has
not previously been performed to any great extent, primarily
because of the technical difficulty in obtaining accurate sequence
of an entire long GAA repeat expansion. Sakamoto et al.
(2001) sequenced 11 expanded FRDA alleles for as long as was
technically possible, up to approximately 200 repeats, and they
identified interruptions in 5 of the 11 samples, which were
clustered within the last 10–15 repeats at the 3′ end. They also
used EarI (GAAGAG recognition sequence) and MnlI (GAGG
recognition sequence) restriction enzyme digestion to identify
specified interruptions within 4 out of 22 FRDA patient samples
(Sakamoto et al., 2001). Subsequently, Holloway et al. (2011)
reported the development of a useful method to determine
non-specified GAA repeat interruptions comprising long-range
GAA PCR followed by MboII (GAAGA recognition sequence)
restriction enzyme digestion. Only four FRDA patients were
investigated in this study, but one of the four was found to
contain an extensive region of GAA repeat interruptions in their
larger 1140 GAA repeat allele, which was partially sequenced to
be (GAA)21(GGAGAA)5(GGAGGAGAA)70(GAA)n. To expand
upon these previous small-number studies, we have now
addressed the question, “Do most FRDA patients have pure GAA
repeat expansions?” by investigating a large panel of 245 FRDA
patient and carrier DNA samples using long-range GAA repeat
PCR amplification and MboII restriction enzyme digestion. We
find that the vast majority (97.8%) of FRDA patient DNA samples
do not contain substantial sequence changes that would result
in abnormal MboII digestion profiles, indicating that they are
primarily pure GAA repeats. We discuss the implications of this




We obtained 245 peripheral blood genomic DNA samples from
FRDA patients (238 samples) and carriers (7 samples) that had
previously undergone GAA repeat expansion size determination
(Supplementary Table S1) (ethics approval granted within the
European Union Seventh Framework Programme [FP7/2007-
2013] under grant agreement number 242193/EFACTS). We also
obtained genomic DNA samples from cerebellum autopsy tissues
from three FRDA patients (tissues were registered with the HTA
under Brunel University Licensing number 12543) and five ear
biopsies from previously described GAA repeat expansion-based
Y47R and YG8sR FRDA mouse models (Anjomani Virmouni
et al., 2015) (animal procedures were carried out in accordance
with the UK Home Office “Animals (Scientific Procedures) Act
1986” and with approval from the Brunel University London
Animal Welfare and Ethical Review Board). We then performed
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long-range PCR of the samples (approximately 100 ng input
DNA) using either the Expand High Fidelity PCR System,
dNTPack (Roche), or the Long Range PCR Kit (Qiagen) together
with GAA-B-F (5′-AATGGATTTCCTGGCAGGACGC-3′) and
GAA-B-R (5′-GCATTGGGCGATCTTGGCTTAA-3′) primers as
previously described (Holloway et al., 2011). The thermocycling
conditions used were (i) Roche Kit: 94◦C for 2 min; 10 cycles of
94◦C for 10 s, 60◦C for 30 s, 68◦C for 45 s; 20 cycles of 94◦C
for 10 s, 60◦C for 30 s, 68◦C for 1 min with 20 s increments;
and a final cycle of 68◦C for 10 mins, or (ii) Qiagen Kit: 93◦C
for 3 min; 35 cycles of 93◦C for 15 s, 62◦C for 30 s, 68◦C for
5 min, and a final cycle of 68◦C for 10 min. The amplified PCR
products contained the GAA trinucleotide repeat expansion with
flanking sequences of 170bp at the 5′ end and 120bp at the 3′ end.
A 5 µl sample of each PCR product was checked by running on
1% agarose gels. The positive samples were then digested with
MboII, which has a cleavage sequence of 5′-GAAGA(8/7)-3′. PCR
sample (17 µl) was digested in a total reaction volume of 20 µl at
37◦C for 1 h. Digested DNA fragments were subjected to heating
at 95◦C for 10 min followed by slow cooling to room temperature
to prevent potential heteroduplex formation, then separated by
running on 2% agarose gels [1% Nusieve (Seakem Agarose GTG)
and 1% Metaphor agarose]. As the MboII restriction enzyme cuts
at the recognition site 5′-GAAGA (8/7)-3′, pure GAA repeats
are completely cut by MboII leaving only two fragments from
the uncut flanking sequences, 171/170bp upstream (designated
hereafter as “170bp”) and 117/118bp downstream (designated
hereafter as “120bp”), which do not contain MboII sites. On the
other hand, if the GAA repeat expansion contains interrupted
GAA sequences that are not cut by MboII, a different pattern of
bands would be obtained upon agarose gel electrophoresis: either
two bands with sizes that differ from the expected 170 and 120bp
or else more than two bands.
DNA Sequencing
GAA PCR products were purified from agarose gels using
Geneclean (MP Biomedicals), then cloned into pCR4.0 using
the TOPO TA cloning kit (Invitrogen). For each PCR product,
plasmid DNA from two independent colonies was Sanger
sequenced by Genewiz using T3 and T7 sequencing primers.
Statistical Analysis
Correlation and regression analysis of GAA repeat sizes versus
age of onset and subsequent ANOVA statistics were performed
using Microsoft Excel data analysis tools (GAA sizes for samples
89–245 were obtained from the EFACTS database).
RESULTS
The Majority of FRDA GAA Repeats Do
Not Contain Interruptions Detected by
MboII Analysis
We examined the GAA repeat status in 245 FRDA patient
and carrier peripheral blood DNA samples by long-range
GAA PCR followed by MboII restriction enzyme digestion
and agarose gel electrophoresis. This method can detect
significant GAA interruptions in either of the two alleles
at a resolution of approximately 20bp added to either
of the two expected MboII bands of 170 and 120bp or
approximately 50bp of internal interruptions (Holloway et al.,
2011). As a positive control for known interrupted FXN
GAA repeat sequence, we used DNA from the “NEP” BAC
transgenic mouse that contains approximately 500 triplet
repeats with the previously determined interrupted sequence
of (GAA)21(GGAGAA)5(GGAGGAGAA)70(GAA)n (Holloway
et al., 2011). Eighteen of our FRDA DNA samples failed to
generate sufficient PCR product for the assay, leaving 227
samples for further analysis; 220 FRDA patients and 7 carriers
(Table 1). 222 out of these 227 samples (97.8%) produced only
the expected two MboII bands of 170 and 120bp, indicating
the likely presence of pure GAA repeats in both alleles in
the vast majority of cases (Figure 1, lanes 2–4). However, the
remaining five samples (2.2%) showed abnormal MboII band
profiles, indicating disruption of at least one of the two alleles.
One sample produced MboII bands of 170 and 200bp, indicating
an insertion of approximately 80bp in the 3′ GAA flanking
sequence (Figure 1, lane 6). Sequencing of the cloned GAA
PCR products from this sample confirmed that there was an
80bp duplication in the 3′ GAA flanking region of the smaller
allele, duplicating the sequence 24–104bp downstream of the
final GAA repeat, that did not involve any interruption of the
GAA repeat itself. Another sample produced MboII bands of
170 and 100bp, indicating a deletion of approximately 20bp in
the 3′ GAA flanking sequence (Figure 1, lane 7). Sequencing of
the cloned GAA PCR products from this sample confirmed that
there was a 19bp deletion of the smaller allele immediately after
the GAA repeat sequence, but not involving any interruption
of the GAA repeat itself. The remaining three abnormal MboII
samples produced bands of approximately 100, 180, and 300bp
(Figure 1, lanes 8–10), but sequencing did not identify any
substantial insertions or deletions in the 5′ or 3′ flanking regions
or in the GAA repeats close to these flanking regions, indicating
the likely presence of significant GAA repeat interruptions
within the body of the GAA repeat expansion alleles and
beyond the capability of our sequencing technology. However,
sequencing of up to 56 repeats at the 5′ and 3′ ends of the
nine FRDA samples shown in Figure 1 did reveal small GAA
repeat sequence interruptions in three of the nine samples (i.e.,
33%) (Figure 1, lane 7 sample: . . .(GAA)23A(GAA)5AGAA, lane
TABLE 1 | Summary of MboII digestion results.






Total no. of samples 245 238 7
Total no. of MboII digestions 227 220 7
170 and 120bp MboII bands only 222 215 7
Other sizes of MboII bands 5 5 0
Confirmed insertion in 3′ flanking region 1 1 0
Confirmed deletion of 3′ flanking region 1 1 0
Unknown change 3 3 0
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FIGURE 1 | MboII digest results. Agarose gel showing MboII digests of GAA PCR products of FRDA samples. The expected 170bp (5′) and 120bp (3′) undigested
GAA-flanking fragments from normal pure GAA repeat expansion FRDA samples are shown in lanes 2, 3, and 4. These band sizes can be seen in between the 200
and 100bp fragments of the 1 Kb+ DNA ladder markers, which are loaded into lanes 1 and 11 of the gel. Lane 5 shows a large MboII band of approximately 600bp
that was obtained from the positive interrupted GAA repeat sequence from the “NEP” BAC transgenic mouse that contains approximately 500 triplet repeats with the
previously determined interrupted sequence of (GAA)21(GGAGAA)5(GGAGGAGAA)70(GAA)n (Holloway et al., 2011). In addition for this positive sample, we also
identified the expected 5′ flanking band of 170bp, together with a smaller band of less than 100bp that we sequenced and we showed to contain a 27bp deletion in
the 3′ flanking region. Lane 6 shows an abnormal band of 200bp representing the 80bp duplication in the 3′ GAA flanking region. Lane 7 shows an abnormal band
of approximately 100bp representing the 19bp deletion in the 3′ GAA flanking region. Lanes 8, 9, and 10 contain abnormal bands of approximately 300, 100, and
180bp, respectively, that are likely to contain a region of interrupted GAA repeat sequence within the body of one or other of the large FRDA GAA repeat expansions.
eight sample:. . .(GAA)26A(GAA)4G(GAA)2 and lane 10 sample:
. . .(GAA)4GAG(GAA)5. These interruptions were all within the
last seven repeats at the 3′ end of the GAA repeat sequence,
in a similar location and at a similar frequency to the small 3′
GAA repeat interruptions that were detected in 5 out of 11 (i.e.,
45%) FRDA samples as previously reported by Sakamoto et al.
(2001).
Confirmation of the Inverse Correlation
Between GAA Repeat Size and Age of
Disease Onset
From our starting cohort of 245 samples, we identified 199
homozygous GAA repeat expansion FRDA patient samples for
which data were available on age of onset in addition to both
GAA repeat allele sizes (Supplementary Table S1). In agreement
with previous studies (Durr et al., 1996; Filla et al., 1996; Reetz
et al., 2015), our analysis of all 199 samples revealed a strong
inverse correlation between the size of the GAA1 allele and age
of onset, with a Pearson’s correlation coefficient, R = −0.58, and
R2 = 0.34, using a linear model, and an even stronger correlation,
R = −0.63, and R2 = 0.40, using a quadratic model (Figure 2 and
Table 2). This would suggest that up to 40% of the variation in
age of onset in our sample collection is determined by GAA1
repeat expansion length. The correlations for either the larger
GAA2 allele repeat size or the average GAA repeat size with age
of onset were also significant, but to a lesser degree (R2 = 0.30
and 0.12, respectively, using a quadratic model, Table 2). The
five samples that showed abnormal MboII band profiles came
from FRDA patients with ages of onset ranging from 5 to
45 years and, therefore, did not reveal any unusual age of onset
subgrouping.
FIGURE 2 | Correlation analysis of GAA repeat size with age of onset. A graph
representing GAA1 repeat size v age of onset is shown (n = 199). The best fit
was for a quadratic model, for which the equations and R2-values are shown
(ANOVA P-values are listed in Table 2).











All GAA1 −0.58 0.34 −0.63 0.40 <0.0001 199
All GAA2 −0.28 0.08 −0.35 0.12 <0.001 199
All average GAA −0.51 0.26 −0.55 0.30 <0.0001 199
Analysis of GAA Repeat Expansion
Dynamics
GAA repeat expansions are known to be dynamic entities,
exhibiting both intergenerational and somatic instability of repeat
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lengths. However, it is possible that GAA repeat expansions may
also vary at either intergenerational or somatic levels according to
sequence content (pure GAA or interrupted repeat sequence). To
address potential intergenerational repeat changes, we identified
four examples of carrier parents and FRDA-affected offspring
within our collection of FRDA patient and carrier DNA samples
(Supplementary Table S1) and examined these samples by MboII
digestion analysis. We found that for all four examples only the
expected two MboII bands of 170 and 120bp were produced
in both parents and offspring, indicating primarily pure GAA
repeats. This indicates that no gross GAA repeat interruptions
detectable by MboII digestion occurred across generations.
Another possible occurrence is that pure GAA sequences may
develop interruptions in different somatic tissues. We addressed
this issue by determining the MboII digestion profiles from
cerebellum autopsy tissue samples from three FRDA patients,
since cerebellum tissue is known exhibit a high degree of GAA
repeat instability in FRDA (Al-Mahdawi et al., 2004). Pure GAA
repeat expansions were identified for each sample, indicating
that, at least in these cases, there was no evidence of tissue-
specific differences of large GAA repeat interruptions that could
be detected by MboII analysis (Figure 3A, lanes 1–3).
Our data obtained from human samples is supported by
similar MboII digestion studies of GAA repeat expansion-based
FRDA YAC transgenic mice. We analyzed DNA samples from
four generations of YG8sR FRDA mice, which have previously
been shown to contain 120 pure GAA repeats (Anjomani
Virmouni et al., 2015). The expected two MboII bands of 170 and
120bp were obtained for all samples, indicating intergenerational
transmission of pure GAA repeats as detected by MboII analysis
(Figure 3B, lanes 3–6). Furthermore, the expected two MboII
bands of 170 and 120bp were obtained for samples of brain,
cerebellum, heart, and liver tissues from the same 1-year-old
YG8sR FRDA mouse, indicating somatic stability of pure GAA
repeats as detected by MboII analysis (Figure 3C, lanes 1–4).
DISCUSSION
To our knowledge, there has been no large-scale study of
FRDA patient DNA samples to determine the frequency of large
interruptions in GAA repeat expansions. Therefore, we aimed to
address the question, “Do most FRDA patients have mainly pure
GAA repeat expansions?” by performing long-range GAA repeat
PCR amplification and MboII restriction enzyme digestion upon
a large panel of 245 FRDA patient and carrier DNA samples.
We found that the majority of GAA repeats from FRDA patient
and carrier samples do not show significant extensive sequence
changes that would result in abnormal MboII profiles, indicative
of primarily pure GAA repeats throughout most of the repeat
length. So the answer to our question is, yes, most FRDA patients
have mainly pure GAA repeat expansions. However, we also
confirmed the previous finding by Sakamoto et al. (2001) that
a significant number of FRDA samples contain small sequence
interruptions localized to the 3′ end of the GAA repeats. These
small localized repeat interruptions would not be detected by
the MboII enzymatic digestion method and they would not be
FIGURE 3 | MboII digests of GAA repeat expansions from human FRDA
somatic tissues and mouse FRDA intergenerational and somatic tissues.
Agarose gels showing MboII digests of GAA PCR products of (A) FRDA
patient cerebellum tissue samples, (B) YG8sR mouse ear biopsy samples and
human FRDA blood samples, and (C) four tissues from one YG8sR mouse. In
each case, the expected 170 and 120bp undigested GAA-flanking fragments
can be identified in between the 200 and 100bp fragments of the 1 Kb+ DNA
ladder marker, which is loaded into the first lane of each gel. (A) Lanes 1–3
show the results from cerebellum tissue samples from three FRDA patients.
(B) Lanes 1 and 2 are from FRDA patient blood samples; lanes 3–6 are from
ear biopsy samples from 4 GAA repeat expansion-based YG8sR mice of four
different generations, and lane 7 is from an ear biopsy sample from the Y47R
mouse which has nine GAA repeats. (C) Lanes 1–4 are from brain,
cerebellum, heart, and liver tissues of the YG8sR mouse, respectively.
expected to have any major impact upon GAA repeat expansion
dynamics in the way that a large MboII-detected interruption
may have.
We recognize that there are some limitations to the MboII
digestion method of analysis. Firstly, MboII digestion does not
identify sequence at the base pair level. Sequencing of long
homozygous GAA repeats, which can be up to 1,700 repeats
in size, is technically still too difficult to perform. However,
sequencing of small GAA repeat alleles is possible after separation
from larger GAA repeat alleles by gel purification techniques. In
future, technologies such as GAA TP-PCR and single molecule
sequencing may prove useful for more detailed analysis of GAA
repeat interruptions in FRDA. TP-PCR studies may allow the
detection of non-GAA interruptions within approximately the
first 100 repeats at the 5′ or 3′ ends of GAA repeat expansions
(Ciotti et al., 2004), although again TP-PCR will not identify
sequence at the base pair level. Alternatively, single molecule
sequencing has been used successfully for the identification
of AGG interruptions in CGG repeats of fragile X syndrome
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premutation individuals (Ardui et al., 2017). Secondly, the MboII
method will only detect approximately 20bp added to the 170
or 120bp flanking regions or >50bp of internal interruptions
in the GAA repeat expansion, but will not detect smaller
interruptions or (GAAGA)n interruptions because these will
be cut by MboII. Furthermore, care must be taken to exclude
possible heteroduplex formation, which may cause difficulties in
interpretation of MboII digests by producing an apparent third
MboII band that is not real.
Overall, our findings indicate that, since most FRDA
patients appear to carry primarily pure GAA repeat expansions
throughout most of the length of the repeat, they are likely to
exhibit a classical FRDA phenotype, showing well established
decreases in frataxin gene expression due to epigenetic changes,
R loop and heterochromatin formation, with consequential
mitochondrial dysfunction, oxidative stress, and cell death,
especially of large sensory neurons (Campuzano et al., 1996;
Saveliev et al., 2003; Groh et al., 2014; Abeti et al., 2015,
2016, 2018a,b). Pure GAA repeat expansions are also likely
to be unstable, increasing in length in aging somatic tissues,
particularly in expansion-susceptible tissues such as the dorsal
root ganglia and cerebellum (De Biase et al., 2007), and thereby
increasing the severity of FRDA disease progression. In contrast,
the lesser number of FRDA patients who may be shown to
have MboII-detected GAA repeat interruptions may have a
less progressive frataxin deficit within their cells and thus a
less severe FRDA disease progression, which may suggest a
prognosis of milder disease. Due to the unstable nature of
pure GAA repeat expansions, individuals with pure GAA repeat
expansions are likely to transmit even larger GAA repeats to any
offspring. However, this may not be the case for individuals with
significant interruptions in their GAA repeat expansions, since
a (GAAAGAA)n interrupted 112 GAA repeat has been reported
to be stably transmitted through two generations (Cossee
et al., 1997). Understanding whether potential FRDA carriers in
the population have either pure GAA repeats or large interrupted
GAA repeats may also be of significance, since large interrupted
GAA repeats may block the appearance of pathologically
sized GAA repeat expansions.
Our findings concerning the paucity of large GAA repeat
interruptions in FRDA also add to the understanding of
trinucleotide repeat disorders in general. It is known that
interruptions within trinucleotide repeat sequences, such as
the (CAG)n ATXN1 repeat, (CTG)n DM1 repeat, and (CGG)n
FMR1 repeat, can make them less prone to expansion. Studies
in yeast have shown that such interruptions in (CTG)n
repeats reduce hairpin formation during DNA replication and
thus inhibit expansion rates (Rolfsmeier and Lahue, 2000).
Other in vitro studies of (CAG)n and (CGG)n repeats have
demonstrated inhibitory effects of interruptions on the formation
of slipped strand DNA structures, thereby reducing their
instability (Pearson et al., 1998). Whatever the exact mechanisms,
the interplay between trinucleotide repeat interruptions and
stability may have important consequences on related genetic
disease phenotype. Thus, the importance of interruptions in
(CAG)n repeat expansions with regard to disease pathology has
previously been reported for spinocerebellar ataxia type 1 (SCA1)
(Menon et al., 2013). Interruptions in the (ATTCT)n repeat
have also been shown to modify the SCA10 disease phenotype
(Matsuura et al., 2006). To this list, we can now add our findings
in FRDA, where large interruptions in the (GAA)n repeat are very
rare and therefore are unlikely to significantly modify the age of
onset FRDA disease phenotype on an overall cohort basis, but
may have significant effects for individual FRDA cases.
Further insights into the relevance of interruptions of
trinucleotide repeats and associated genetic diseases may be
gained by studying suitable mouse models. For example, the
comparison of FRDA and Huntington disease (HD) transgenic
and knock-in mice also sheds some light on our understanding
of the importance of trinucleotide repeat sequence content,
somatic instability, and disease phenotype. Both CAG transgenic
and CAG knock-in mice can give rise to HD-like phenotypes.
However, both of the HD transgenic mice, BACHD and YAC128,
contain interrupted repeats (Pouladi et al., 2012), which in
both cases leads to complete somatic stability, whereas the
three HD knock-in mice (Shelbourne et al., 1999; Wheeler
et al., 1999; Ishiguro et al., 2001) have pure CAG repeats and
extensive somatic instability. Further studies of HD transgenic
mice with pure CAG repeats and knock-in mice with interrupted
repeats should help to sort out the underlying mechanisms
here. The same is true for investigations of the GAA repeats
of FRDA mouse models. YG8R and KIKO mice have pure
GAA repeats and extensive somatic and intergenerational GAA
repeat instability with a bias toward expansion, whereas the BAC
transgenic mice have extensive interruptions in the GAA repeat
sequence and show no somatic instability (Al-Mahdawi et al.,
2004). However, this does not translate directly into a significant
difference in disease phenotype since all three FRDA mouse
models exhibit similarly mild FRDA-like phenotypes (Miranda
et al., 2002; Al-Mahdawi et al., 2006). Our reported finding
now that YG8sR FRDA YAC transgenic mice contain pure GAA
repeats that remain uninterrupted throughout intergenerational
transmission and across different somatic tissues means that such
mice will be liable to further expansion of the GAA repeat size
across generations and within tissues throughout age. It will be
interesting to see how increasing GAA repeat sizes correlate with
FRDA-like disease severity in these mice.
CONCLUSION
We have shown that major interruptions of GAA repeat
expansions are very rare, but when they do occur, they may
be of importance to FRDA disease progression, in a similar
manner to interruptions in other trinucleotide repeat sequences
and their associated genetic diseases. In contrast, we have
confirmed that small GAA repeat sequence interruptions occur
more frequently at the 3′ end of the GAA repeat sequence, but
such small interruptions are not expected to have such a major
impact on GAA repeat expansion dynamics. Ultimately, future
studies that enable GAA repeat expansion sequence verification
at the base pair resolution are needed to allow further in depth
conclusions to be made regarding the importance of GAA repeat
interruptions and FRDA disease.
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